Join the Brolucizumab group to help and get support from people like you.
Brolucizumab News
Novartis Announces FDA Approval of Beovu for the Treatment of Diabetic Macular Edema
Approval is based on year one data from the Phase III KESTREL and KITE clinical trials investigating Beovu (brolucizumab-dbll) 6 mg versus aflibercept 2 mg in DME patients1,2 In KESTREL and KITE,...
FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)
EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the...
Further information
Related condition support groups
Diabetic Macular Edema, Macular Degeneration